Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content
Click to go back to the Pipeline page Back To Explore Our Pipeline

Disable motion

XL092: TKI

XL092 is a next-generation oral multi-targeted tyrosine kinase inhibitor discovered and developed by Exelixis.
XL092 inhibits multiple receptor tyrosine kinases (RTKs), including VEGFR, MET, TAM kinases (AXL and MER), and other kinases implicated in the growth and spread of cancer.
Phase 1 dose-escalation and expansion study of XL092 as single-agent and combination therapy in inoperable locally advanced or metastatic solid tumors
Cohort Expansions
For more information, visit
clinicaltrials.gov/NCT03845166.
Phase 1b dose-escalation and expansion study of XL092 in combination with immuno-oncology agents in unresectable advanced or metastatic solid tumors
Cohort Expansions
For more information, visit
clinicaltrials.gov/NCT05176483.
Phase 3 randomized, open-label study of XL092 with atezolizumab vs regorafenib in metastatic colorectal cancer
For more information, visit
clinicaltrials.gov/NCT05425940.
This website includes information on investigational uses of compounds that have not been approved by FDA. Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.
Explore All
Pipeline Clinical Trials
Click to go to Resource